Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment.
The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.
Memory rehabilitation for people with multiple sclerosis.
Demyelination: the role of reactive oxygen and nitrogen species.
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
FDA warns about seizures linked to MS drug
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
The little compound that could: how phenytoin changed drug discovery and development.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Anejaculatory infertility due to multiple sclerosis.
Physiopathology of symptoms and signs in multiple sclerosis.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.

Pages